Ameliorating effects of the immunomodulator 3-(2-ethylphenyl)-5-(3- methoxyphenyl)-1H-1,2,4-triazole in an experimental model of colitis in the rat

European Journal of Pharmacology

Volumn 494, Issue 2-3, 2004, Pages 263-272

  Stasi, Maria Antonietta ^a   Ruggiero, Vito ^a   Ursillo, Angela ^a   Taurelli, Roberto ^a   Aglianò, Margherita ^b   Weber, Elisabetta ^b   Lorenzoni, Paola ^b   Sorrentino, Vincenzo ^b   Pacifici, Licia ^a   Carminati, Paolo ^a  

^a Sigma Tau SpA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Inflammatory bowel disease; Interferon ; Interleukin 10; Myeloperoxidase; TNBS; Tumour necrosis factor

Indexed keywords

3 (2 ETHYLPHENYL) 5 (3 METHOXYPHENYL) 1H 1,2,4 TRIAZOLE; ALCOHOL; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; MYELOPEROXIDASE; ST 1959; TRIAZOLE DERIVATIVE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON MUCOSA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOMODULATION; INTESTINE WALL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; THICKNESS; TIME;

ANIMALS; BODY WEIGHT; COLITIS; COLON; CYTOKINES; DIARRHEA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MALE; NEUTROPHIL INFILTRATION; ORGAN SIZE; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES; TRINITROBENZENESULFONIC ACID;

EID: 2942755815     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.05.014     Document Type: Article

References (45)

1. Bach J.F. Non-Th2 regulatory T-cell control of Th1 autoimmunity. Scand. J. Immunol. 54:2001;21-29
2. Blumberg R.S., Saubermann L.J., Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr. Opin. Immunol. 11:1999;648-656
3. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with a enzyme marker. J. Invest. Dermatol. 78:1982;206-209
4. Camoglio L., Te Velde A.A., Tigges A.J., Das P.K., Van Deventer S.J. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm. Bowel Dis. 4:1998;285-290
5. Cuzzocrea S., Mazzon E., Dugo L., Caputi A.P., Riley D.P., Salvemini D. Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis. Eur. J. Pharmacol. 432:2001;79-89
6. De Waal Malefyt R., Yssel H., Roncarolo M.G., Spits H., De Vries J.E. Interleukin-10. Curr. Opin. Immunol. 4:1992;314-320
7. D'Haens G. Anti-TNF therapy for Crohn's disease. Curr. Pharm. Des. 9:2003;289-294
8. Elson C.O., Sartor R.B., Tennyson G.S., Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology. 109:1995;1344-1367
9. Fiorentino D.F., Bond M.W., Mosmann T.R. Two types of mouse T helper cell: IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:1989;2081-2095
10. Fuss I.J., Marth T., Neurath M.F., Pearlstein G.R., Jain A., Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 cells in experimental colitis in mice. Gastroenterology. 117:1999;1078-1088
11. Galliani G., Assandri A., Gallico L., Luzzani F., Oldani C., Omodei-Sale A., Soffientini A., Lancini G. A new non-hormonal pregnancy-terminating agent. Contraception. 23:1981;163-180
12. Gibson P.R., Anderson R.P. Inflammatory bowel disease. Med. J. Aust. 169:1998;387-394
13. Glimcher L.H., Murphy K.M. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev. 14:2000;1693-1711
14. Guo X., Wang W.P., Ko J.K., Cho C.H. Involvement of neutrophils and free radicals in the potentiating effects of passive cigarette smoking on inflammatory bowel disease in rats. Gastroenterology. 117:1999;884-892
15. Hanauer S.B., Present D.H. The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 3:2003;81-92
16. Kirsner J.B. Experimental colitis with particular reference to hypersensitivity reactions in the colon. Gastroenterology. 40:1961;307-312
17. Kiss J., Lamarque D., Delchier J.C., Whittle B.J.R. Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Eur. J. Pharmacol. 336:1997;219-224
18. Lienenluke B., Stojanovic T., Fiebig T., Fayyazi A., Germann T., Hecker M. Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat-role of endothelial cell-leukocyte interaction. Br. J. Pharmacol. 133:2001;1414-1423
19. Lindsay J., Van Montfrans C., Brennan F., Van Deventer S., Drillenburg P., Hodgson H., Te Velde A.A., Sol Rodriguez Pena M. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther. 9:2002;1715-1721
20. Martinsson T., Ljung T., Rubio C., Hellstrom P.M. Beneficial effects of ropivacaine in rat experimental colitis. J. Pharmacol. Exp. Ther. 291:1999;642-647
21. Mistrello G., Galliani G., Assandri A., Filippeschi S., Bassi L. Immunological profile of DL 111-IT, a new immunosuppressant agent. Immunopharmacology. 10:1985;163-169
22. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 96:1989;795-803
23. Mullane K.M., Kraemer R., Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Methods. 14:1985;157-167
24. Nash S., Stafford J., Madara J.L. Effects of polymorphonuclear leukocyte transmigration and barrier function of cultured intestinal epithelial monolayers. J. Clin. Invest. 80:1987;1104-1113
25. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182:1995;1281-1290
26. Neurath M.F., Fuss I., Strober W. TNBS-colitis. Int. Rev. Immunol. 19:2000;51-62
27. Neurath M.F., Finotto S., Glimcher L.H. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8:2002;567-573
28. Palmen M.J.H.J., Dijkstra C.D., Van der Ende M.B., Pena A.S., Van Rees E.P. Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats. Clin. Exp. Immunol. 101:1995;351-356
29. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 347:2002;417-429
30. Podolsky D.K. The future of IBD treatment. J. Gastroenterol. 38:2003;63-66
31. Ribbons K.A., Thompson J.H., Liu X., Pennline K., Clark D.A., Miller M. Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis. Eur. J. Pharmacol. 323:1997;245-254
32. Ruggiero V., Albertoni C., Rosi A., Leoni B., Carminati P., De Santis R. Efficacy of ST1959 in murine models of autoimmunity and insights into its peculiar immunomodulatory profile. Int. J. Immunother. 19:2003;1-10
33. Rutgeerts P. Medical therapy of inflammatory bowel disease. Digestion. 59:1998;453-469
34. Sandborn W.J., Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology. 122:2002;1592-1608
35. Sartor R.B. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 106:1994;533-539
36. Scheinin T., Butler D.M., Salway F., Scallon B., Feldmann M. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin. Exp. Immunol. 133:2003;38-43
37. Schreiber S., Heinig T., Thiele H.G., Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 108:1995;1434-1444
38. Schwab M., Schaffeler E., Marx C., Fischer C., Lang T., Behrens C., Gregor M., Eichelbaum M., Zanger U.M., Kaskas B.A. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 12:2002;429-436
39. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 120:2001;622-635
40. Ten Hove T., Corbaz A., Amitai H., Aloni S., Belzer I., Graber P., Drillenburg P., van Deventer S.J., Chvatchko Y., Te Velde A.A. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology. 121:2001;1372-1379
41. Villegas I., La Casa C., Orjales A., Alarcon de la Lastra C. Effects of dosmalfate, a new cytoprotective agent, on acute and chronic trinitrobenzene sulphonic acid-induced colitis in rats. Eur. J. Pharmacol. 460:2003;209-218
42. Ward M. The pathogenesis of Crohn's disease. Lancet. 2:1977;903-905
43. Wirtz S., Neurath M.F. Animal models of intestinal inflammatory: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int. J. Colorectal Dis. 15:2000;144-160
44. Yamada T., Zimmerman B.J., Specian R.D., Grisham M.B. Role of neutrophils in acetic acid-induced colitis in rats. Inflammation. 15:1991;399-411
45. Yang B., Zhou H.J., He Q.J., Fang R.Y. Termination of early pregnancy in the mouse, rat and hamster with DL111-IT and RU486. Contraception. 62:2000;211-216